A phase II research found that pyrotinib in combination with trastuzumab and chemotherapy provides an active alternative with a favorable safety profile in patients with HER2-positive metastatic BC who have been intensively pre-treated [11]. This evidence concerns the gene ERBB2 and breast cancer.